Giovanni Caforio to be made chairman of the board at BMS
pharmafile | January 3, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Bristol-Myers Squibb, Giovanni Caforio, bristol myers-squibb
Bristol-Myers Squibb has announced that Giovanni Caforio has been appointed chairman of the board. Caforio will take up the position on 2 May, which is the date of the company’s annual meeting of shareholders. Caforio will hold the position alongside his current role of chief executive officer of BMS, which he has held for the past one year and nine months. He has been with BMS for 16 years, at present. Prior to working at BMS, he held various positions at Abbott Laboratories.
“It is an honour to have the opportunity to build on the strong foundation established by Lamberto Andreotti,” said Caforio. “Bristol-Myers Squibb has tremendous opportunities for growth, highlighted by our leadership position in Immuno-Oncology and the opportunity to accelerate our diversified pipeline of transformational medicines. Working with the talented leaders and employees of this company, I look forward to further advancing our BioPharma strategy, and delivering transformational medicines that make a difference in the lives of patients around the world.”
Related Content
NICE approves first treatment for obstructive HCM for NHS use
The National Institute for Health and Care Excellence (NICE) has announced that it has approved …
Bristol Myers Squibb psoriasis drug shows positive Phase III results
Bristol Myers Squibb’s investigational deucravacitinib drug, for the treatment of moderate-to-severe plaque psoriasis, has shown …
Molecular Templates signs cancer deal with BMS worth up to $1.3bn
Molecular Templates and Bristol Myers Squibb have entered into a worldwide strategic research collaboration worth …